Remove 2023 Remove Access Remove DEA
article thumbnail

The Year in Weed: 2023 Edition

The Blunt Truth

We thought the market would expand “quite a bit” in 2023 – well, the “a bit” part was right. And not to ruin the ending, but no retail market will open in 2023. As of now, this is still a proposal, and it’s anyone’s guess if the DEA (who would do the actual re-scheduling) will think that’s a good idea. by a large margin.

DEA 52
article thumbnail

SXSW Opens Voting On Nearly 100 Cannabis And Psychedelics Panels For 2023 Festival

Cannabis Law Report

Marijuana Moment report on some of the panels being proposed for 2023…… Voting is now open for the public to decide which panels will make the stage at next year’s South By Southwest (SXSW) festival—and there are about 100 marijuana- and psychedelics-related proposals to pick from. Which Political Party Will Legalize Weed?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Emerge Law Group (OR): PSILOCYBIN THERAPY FOR PATIENTS WITH ADVANCED ILLNESS IN OREGON

Cannabis Law Report

Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment. Access Pursuant to the Oregon Psilocybin Services Act. Access to Psilocybin Therapy Pursuant to Right to Try Laws.

Therapy 52
article thumbnail

HSS Releases Full Recommendation Report for Rescheduling Cannabis: What Will This Mean for Med & Rec Markets?

Veriheal

Department of Health and Human Services (HHS) recommended that the Drug Enforcement Agency (DEA) reshedule cannabis as a Schedule III substance in August of 2023. Speaking about research and development, think about all the new cannabis studies that can happen when you allow researchers to more easily access the plant.

article thumbnail

Psychedelic Users Tend to Be ‘One With Nature’ and Are More Passionate About Climate Change, Study Finds

Veriheal

In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. . It’s excellent news, particularly since new research suggests psilocybin deserves further investigation.

article thumbnail

Final Phase of MDMA Clinical Trials Shows Drug Is 90% Effective at Treating PTSD

SpeedWeed

Doblin and his fellow researchers initially began exploring the therapeutic potential of MDMA back in the early 1980s, but these studies ground to a halt when the DEA banned ecstasy in 1985. MAPS is now enrolling participants for a further Phase 3 study that will allow another 50 subjects to access this promising new therapy.

article thumbnail

Understanding the Current Legal Status of Psychedelics in the United States

Cannabis Law Report

The only opportunity to currently participate would be through an active clinical trial or via an argument under the Right to Try Act of 2018 (an act which provides a pathway for patients with life-threatening diseases or conditions to access unapproved treatments). Emerging Non-Medical State-Regulated Path. Non-Commercial Operations.